Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL-2 and Therapeutic Vaccines in Primary HIV Infection
NCT00196651Phase 2Terminated
- Sponsor
- ANRS
- Start
- Aug 2000
- Modality
- Cytokines & Interferons, Peptides, Vaccines & Immunotherapeutics
01
Overview
Phase 2, randomised, open-label trial of aldesleukin, ALVAC-HIV 1433 and LIPO-6T in human immunodeficiency virus infection (HIV) (3 arms), sponsored by ANRS. Primary endpoint: Evolution of CD4-CD8 non specific and HIV specific cells, vaccinal peptids and viral load with DNA proviral at 36 weeks. Started Aug 2000; status: terminated.
02
Drugs
aldesleukinALVAC-HIV 1433LIPO-6T
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00196651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00196651.